替诺福韦/恩曲他滨联合洛匹那韦/利托那韦或考比司他/埃替格韦单片方案用于HIV暴露后预防
一项前瞻性开放随机对照试验,将符合HIV暴露后预防(PEP)标准的个体按1:3随机分配接受替诺福韦/恩曲他滨联合洛匹那韦/利托那韦或考比司他/埃替格韦单片方案。结果显示洛匹那韦/利托那韦组第28天PEP未完成率、依从性差和不良事件均显著更高,提示考比司他/埃替格韦单片方案耐受性良好。
要点
- 洛匹那韦/利托那韦组第28天PEP未完成率有更高趋势(47% vs 33%,P=0.10)。
- 改良ITT分析中洛匹那韦/利托那韦组PEP未完成率显著更高(33% vs 15%,P=0.04)。
- 洛匹那韦/利托那韦组依从性差和不良事件显著更常见,考比司他/埃替格韦耐受性更好。
核心结论
- 洛匹那韦/利托那韦组PEP未完成率更高、依从性更差且不良事件更多,提示考比司他/埃替格韦单片方案是耐受性良好的PEP抗逆转录病毒选择。
研究设计与样本
- 前瞻性、开放、随机临床试验,因潜在性暴露于HIV且符合PEP标准的个体随机1:3分组。
- 洛匹那韦/利托那韦组n=38,考比司他/埃替格韦组n=119,两组均联合替诺福韦/恩曲他滨。
- 计划在第1、10、28、90和180天进行五次随访,主要终点为第28天PEP未完成率。
主要发现
- 中位年龄32岁,95%为男性。
- 第28天PEP未完成率为36%(n=57),洛匹那韦/利托那韦组47%(n=18)vs 考比司他/埃替格韦组33%(n=39),P=0.10。
- 改良ITT分析(仅纳入第1天就诊者)中,洛匹那韦/利托那韦组PEP未完成率33% vs 考比司他/埃替格韦组15%,P=0.04。
- 依从性差在洛匹那韦/利托那韦组显著更高(47% vs 9%,P<0.0001)。
- 不良事件报告73例(59%),洛匹那韦/利托那韦组显著更常见(90% vs 49%,P=0.0001);考比司他/埃替格韦组观察到1例血清转换,该患者在PEP前后有多次暴露。
关键数值与推荐
- PEP未完成率:洛匹那韦/利托那韦组47% vs 考比司他/埃替格韦组33%(P=0.10)。
- 改良ITT分析PEP未完成率:洛匹那韦/利托那韦组33% vs 考比司他/埃替格韦组15%(P=0.04)。
- 依从性差:洛匹那韦/利托那韦组47% vs 考比司他/埃替格韦组9%(P<0.0001)。
- 不良事件:洛匹那韦/利托那韦组90% vs 考比司他/埃替格韦组49%(P=0.0001)。
临床怎么用
- 对于符合PEP标准的个体,考比司他/埃替格韦单片方案可能因更好的耐受性和依从性而优于洛匹那韦/利托那韦方案。
- 处方PEP时应考虑不良事件和依从性对完成率的影响,优先选择耐受性更好的单片方案。
局限性
- 开放标签设计可能影响依从性和不良事件报告。
- 洛匹那韦/利托那韦组样本量较小(n=38),统计效能有限。
- 改良ITT分析仅纳入第1天就诊者,可能引入选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess HIV-1 post-exposure prophylaxis (PEP) non-completion at day 28, comparing ritonavir-boosted lopinavir versus cobicistat-boosted elvitegravir as a single-tablet regimen (STR), using tenofovir disoproxil fumarate/emtricitabine with both of these therapies. METHODS: A prospective, open, randomized clinical trial was performed. Individuals attending the emergency room due to potential sexual exposure to HIV and who met criteria for PEP were randomized 1:3 into two groups receiving either 400/100 mg of lopinavir/ritonavir (n = 38) or 150/150 mg of elvitegravir/cobicistat (n = 119), with both groups also receiving 245/200 mg of tenofovir disoproxil fumarate/emtricitabine. Five follow-up visits were scheduled at days 1, 10, 28, 90 and 180. The primary endpoint was PEP non-completion at day 28. Secondary endpoints were adherence, adverse effects and rate of seroconversions. Clinical trials.gov number: NCT08431173. RESULTS: Median age was 32 years and 95% were males. PEP non-completion at day 28 was 36% (n = 57), with a trend to be higher in the lopinavir/ritonavir arm [lopinavir/ritonavir 47% (n = 18) versus elvitegravir/cobicistat 33% (n = 39), P = 0.10]. We performed a modified ITT analysis including only those patients who attended on day 1. PEP non-completion in this subgroup was higher in the lopinavir/ritonavir arm than in the elvitegravir/cobicistat arm (33% versus 15%, respectively, P = 0.04). Poor adherence was significantly higher in the lopinavir/ritonavir arm versus the elvitegravir/cobicistat arm (47% versus 9%, respectively, P < 0.0001). Adverse events were reported by 73 patients (59%), and were significantly more common in the lopinavir/ritonavir arm (90% versus 49%, P = 0.0001). A seroconversion was observed in the elvitegravir/cobicistat arm in a patient with multiple exposures before and after PEP. CONCLUSIONS: A higher PEP non-completion, poor adherence and adverse events were observed in patients allocated to the lopinavir/ritonavir arm, suggesting that STR elvitegravir/cobicistat is a well-tolerated antiretroviral for PEP.
引用
- Inciarte A, Leal L, González E, et al. Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis. J Antimicrob Chemother. 2017. PMID: 29091217. doi:10.1093/jac/dkx246
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。